Medical terminology course buy neurontin online required.

Migraine. The promotion of prescription drugs directly to the public is not allowed in the European Union. But see the Ajovy case in Spain: direct-to-consumer news, the blurred margin between propaganda and information.

15 Mar

It seems that Teva’s commercial strategy includes promoting fremanezumab (Ajovy) to the general public (direct-to-consumer).  Vall d’Hebron Hospital (Barcelona, Spain) supports and presents as a novelty something that “offers nothing new”.  Such promotion is clearly prohibited by Spanish and European legislation.  It is also accompanied by an incredible and constant “apparatus” of pressure on those who “benefit” socially and financially through conferences, consensus statements, guidelines, publications, seminars, and other means.
  • In Spain, direct-to-consumer advertising of fremanezumab (Ajovy), February 2026. Migraine.Gérvas J. Madrid, Spain. March 2026. Download article here.

Letter to “NoGracias” from a patient suffering migraine. Boicot a Teva and the boycott of Ajovy (fremanezumab). A clinical case.

12 Mar

Teva employs multiple mechanisms to maintain its business, from corruption to direct publicity, including the manipulation of opinion leaders (professionals and patients). Nothing compares to the impact of someone who suffers and “plays” in favor of Teva and against science and ethics. A personal narrative of suffering negates all the work that underpins rational and sensible decisions. We present a “clinical case”: a patient suffering from migraines, for whom Ajovy (from Teva) has restored “normality” (even though it is a medication that is neither effective nor safe).
  • Letter to “NoGracias” from a patient suffering migraine. Boicot a Teva and the boycott of Ajovy (fremanezumab). A clinical case. Health Workers For Palestine, Spain (HW4PS) and NoGracias. Madrid, Spain. March, 2026. Download article here.

When family and societal expectations outweigh science. The case of ataluren for Duchenne.

12 Mar

Duchenne muscular dystrophy is a neurodegenerative disease with no current cure.
In 2014, the FDA and EMA evaluated a new drug for this condition: ataluren. Ataluren was not approved by the FDA due to a lack of efficacy in Duchenne muscular dystrophy, while the EMA granted conditional approval.
After marketing authorization in the EU, the EMA allowed the company to continue performing trials to demonstrate efficacy.
The Spanish National Health System issued a resolution denying reimbursement of this drug due to lack of efficacy. In Spain, virtually all Regional Health Services overruled the Ministry of Health and reimbursed ataluren to Duchenne patients using their own resources, yielding to social pressure and/or seeking political benefit.
A study on the effectiveness of ataluren within Spain National Health System was started, but couldn´t be completed due to lack of involvement from the Regional Health Services.
The cost per patient is estimated at approximately €200,000 annually.
Eleven years later, the EMA withdraws the conditional authorization of the drug after repeated failure to prove efficacy.
  • When family and societal expectations outweigh science. The case of ataluren for Duchenne. Gérvas J. Madrid, Spain. December 2025. Download article here.

“Trump is crazy” is a reassuring, simple, and false explanation! Mad people are good people. Scoundrels are not

12 Mar

Leaders like Trump and Netanyahu are not an aberration but the expected expression of a regime where mediation collapses, where the state merges with the leader’s desires, and where obscenity becomes a legitimate political response. Thus, the “madness” of accusing of terrorism anyone who writes or shouts “Long live free Palestine!”, or the Big Brother-style control of social media to maintain an official narrative on “thorny issues” such as the US siege of Venezuela or apartheid and genocide in Palestine. In reality, it is not “madness,” but a perverse mechanism connected to institutions that promote and authorize excesses “above” (leaders) and “below” (violent groups). We tend to accept that illness justifies everything; it’s the progressive medicalization of daily life, including, in this case, the overwhelming presence of scoundrels among the leaders (at the top) and violent organizations (at the bottom). They aren’t sick. They are scoundrels, selected, promoted, and legitimized in their actions.

Vaccines are not seat belts, and motor vehicles are not human beings

10 Apr

The debate on the coercive vaccination is raised many times with the example of the acceptance of the implementation of the mandatory use of  seat belts in motor vehicles. It is a very popular approach usually led by those who lack scientific training in vaccines. Seat belts are no vaccines, and motor vehicles are not human beings so the ethical foundation of coercive seat belts laws does not apply to coercive vaccination policies. Mandatory vaccination, which already exists in some countries, is being promoted when the outbreaks of vaccine preventable diseases are presented as the responsibility of the “anti-vaccines”. But “anti-vax” are residuals in the world.
  • Vaccines are not seat belts, and motor vehicles are not human beings. Gérvas J, Pérez-Fernández M. Madrid, Spain. April 2024. Download article here.

Veoza (fezolinetant) for hot flushes in menopause – think twice!

20 Jan

During the climacteric period, before, during and after the menopause, hot flushes are common. In general they can be endured without great discomfort and subside with time, but there are cases of great intensity and persistence. This paper discusses the marketing of Veoza (fezolinetant) for the relief of hot flushes. The issue is that it is an expensive, ineffective drug with significant adverse effects.
  • Veoza (fezolinetant) for hot flushes in menopause – think twice!  Pérez-Fernández M, Gérvas J. Madrid, Spain. January 2024. Download article here.

The European Alliance for Responsible R&D and Affordable Medicines transparency of clinical trials and good governance should be included in the EMA (European Medicines Agency) extended mandate

13 Sep

In occasion of the ongoing trilogues on the European Medicines Agency (EMA) extended mandate, Members of the European Alliance for Responsible R&D and Affordable Medicines urge the Council to ensure the new Regulation enhances clinical trial transparency and upholds good governance.    As explained in a letter published today, it is crucial that information on clinical trials is made available in a timely, user-friendly, and complete manner. This is key to avoid unnecessary duplications and to accelerate the development of new therapies and vaccines, especially during a public health emergency.
  • The European Alliance for Responsible R&D and  Affordable Medicines transparency of clinical trials and good governance should be included in the EMA (European Medicines Agency) extended mandate. Brussels, Belgium, 9 September 2021 Download article here.
« previous